Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sail Biomedicines eRNA malaria vaccine
- Development stage
- Preclinical
- Lead developer
- Sail Biomedicines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Sail Biomedicines eRNA malaria vaccine is an investigational prophylactic vaccine candidate developed in collaboration with the Bill & Melinda Gates Foundation. It utilizes Sail's proprietary Endless RNA (eRNA) platform, which employs engineered circular RNA designed for enhanced stability and prolonged protein expression compared to traditional linear mRNA. This specific vaccine candidate is designed to express a transmembrane protein that targets and activates antigen-presenting cells (APCs) to elicit a robust and durable immune response against the malaria parasite. Administered via intramuscular injection, the program aims to provide a more effective alternative to current malaria prevention strategies by leveraging the unique properties of circular RNA to stimulate the immune system directly through APC engagement.
- Other names
- Malaria vaccine (Gates Foundation)eRNA malaria vaccineAPC-targeted malaria vaccine
Beyond the preview
Go deeper on Sail Biomedicines eRNA malaria vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sail Biomedicines eRNA malaria vaccine.